DEF: Disc Medicine Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Disc Medicine announces its 2025 Annual Meeting of Stockholders to be held virtually on June 11, 2025, featuring director elections, executive compensation votes, and auditor ratification.

Summary

• Disc Medicine, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, at 9:00 A.M. Eastern Time.
• Stockholders of record as of April 15, 2025, are eligible to vote on several key proposals.
• The proposals include the election of three Class II directors, an advisory vote on executive compensation, an advisory vote on the frequency of future executive compensation votes, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The board of directors recommends voting FOR the election of the director nominees, FOR the approval of executive compensation, FOR holding an annual advisory vote on executive compensation, and FOR the ratification of the appointment of Ernst & Young LLP.
• The company is furnishing proxy materials online, with instructions provided to stockholders on how to access these materials and request a print version.
• As of April 15, 2025, there were 34,632,936 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and factual manner. The recommendations for voting 'for' the proposals suggest a positive outlook from the board's perspective.

Positives

• The company is utilizing a virtual-only meeting format to enhance stockholder access and participation.
• The board of directors is recommending a vote FOR all proposals, indicating confidence in the company's direction and management.
• The company is providing stockholders with expedited access to proxy materials online, reducing costs and environmental impact.

Future Outlook

The company is seeking stockholder approval for key proposals that will guide its governance and strategic direction in the coming year.

Management Comments

• John Quisel, J.D., Ph.D., President and Chief Executive Officer, encourages stockholders to vote and ensure their shares are represented.

Industry Context

This announcement is a standard part of corporate governance for publicly traded companies, ensuring stockholders have a voice in key decisions.

Stakeholder Impact

• Stockholders have the opportunity to influence the company's direction through their votes.
• The outcome of the votes will impact the composition of the board of directors, executive compensation, and the selection of the company's auditor.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 11, 2025, and announce the voting results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Ernst & Young, Voting, Governance, Disc Medicine